Muscle pain in models of chemotherapy-induced and alcohol-induced peripheral neuropathy

Annals of Neurology

Volumn 70, Issue 1, 2011, Pages 101-109

  Alvarez, Pedro ^a   Ferrari, Luiz F ^a   Levine, Jon D ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ANTISENSE OLIGODEOXYNUCLEOTIDE; OXALIPLATIN; PACLITAXEL; PROTEIN KINASE C EPSILON;

ALCOHOL CONSUMPTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; GASTROCNEMIUS MUSCLE; HYPERALGESIA; MALE; MYALGIA; NEUROPATHIC PAIN; NEUROTOXICITY; NOCICEPTION; NONHUMAN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RAT; SKIN;

ALCOHOL DRINKING; ALCOHOLIC NEUROPATHY; ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE MODELS, ANIMAL; MALE; MUSCLE, SKELETAL; PAIN; PAIN MEASUREMENT; PERIPHERAL NERVOUS SYSTEM DISEASES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 79959978806     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.22382     Document Type: Article

References (57)

1. Costigan M, Scholz J, Woolf CJ,. Neuropathic pain: a maladaptive response of the nervous system to damage. Annu Rev Neurosci 2009; 32: 1-32.
2. Marchettini P, Formaglio F, Lacerenza M,. Clinical interpretations of intraneural muscle nociceptors recordings in humans. J Musculoskelet Pain 1999; 7: 55-59. (Pubitemid 29447905)
3. Bradley WG, Lassman LP, Pearce GW, Walton JN,. The neuromyopathy of vincristine in man. Clinical, electrophysiological and pathological studies. J Neurol Sci 1970; 10: 107-131.
4. Gardner AJ,. Neuropathy after alcohol withdrawal. J Neurol Neurosurg Psychiatry 1972; 35: 323-325.
5. Kunitoh H, Saijo N, Furuse K, et al. Neuromuscular toxicities of paclitaxel 210 mg m(-2) by 3-hour infusion. Br J Cancer 1998; 77: 1686-1688. (Pubitemid 28230475)
6. Vittadini G, Buonocore M, Colli G, et al. Alcoholic polyneuropathy: a clinical and epidemiological study. Alcohol Alcohol 2001; 36: 393-400. (Pubitemid 32851420)
7. Peltier AC, Russell JW,. Advances in understanding drug-induced neuropathies. Drug Saf 2006; 29: 23-30. (Pubitemid 43213893)
8. van de Glind G, de Vries M, Rodenburg R, et al. Resting muscle pain as the first clinical symptom in children carrying the MTTK A8344G mutation. Eur J Paediatr Neurol 2007; 11: 243-246. (Pubitemid 46832168)
9. Jacobson SD, Loprinzi CL, Sloan JA, et al. Glutamine does not prevent paclitaxel-associated myalgias and arthralgias. J Support Oncol 2003; 1: 274-278.
10. Baron R,. Mechanisms of disease: neuropathic pain - a clinical perspective. Nat Clin Pract Neurol 2006; 2: 95-106. (Pubitemid 43210250)
11. Dina OA, Barletta J, Chen X, et al. Key role for the epsilon isoform of protein kinase C in painful alcoholic neuropathy in the rat. J Neurosci 2000; 20: 8614-8619.
12. Dina OA, Chen X, Reichling D, Levine JD,. Role of protein kinase Cepsilon and protein kinase A in a model of paclitaxel-induced painful peripheral neuropathy in the rat. Neuroscience 2001; 108: 507-515. (Pubitemid 34037894)
13. Reichling DB, Levine JD,. Critical role of nociceptor plasticity in chronic pain. Trends Neurosci 2009; 32: 611-618.
14. Zhang Y, Wang YH, Zhang XH, et al. Proteomic analysis of differential proteins related to the neuropathic pain and neuroprotection in the dorsal root ganglion following its chronic compression in rats. Exp Brain Res 2008; 189: 199-209.
15. Polomano RC, Mannes AJ, Clark US, Bennett GJ,. A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel. Pain 2001; 94: 293-304. (Pubitemid 33145399)
16. Joseph EK, Levine JD,. Comparison of oxaliplatin- and cisplatin-induced painful peripheral neuropathy in the rat. J Pain 2009; 10: 534-541.
17. Lieber CS, DeCarli LM,. The feeding of alcohol in liquid diets: 2 decades of applications and 1982 update. Alcohol Clin Exp Res 1982; 6: 523-531. (Pubitemid 13201236)
18. Lieber CS, DeCarli LM,. Liquid diet technique of ethanol administration: 1989 update. Alcohol Alcohol 1989; 24: 197-211. (Pubitemid 19187575)
19. Dina OA, Messing RO, Levine JD,. Ethanol withdrawal induces hyperalgesia mediated by PKCepsilon. Eur J Neurosci 2006; 24: 197-204. (Pubitemid 44050679)
20. Takahashi K, Taguchi T, Itoh K, et al. Influence of surface anesthesia on the pressure pain threshold measured with different-sized probes. Somatosens Mot Res 2005; 22: 299-305.
21. Nasu T, Taguchi T, Mizumura K,. Persistent deep mechanical hyperalgesia induced by repeated cold stress in rats. Eur J Pain 2010; 14: 236-244.
22. Murase S, Terazawa E, Queme F, et al. Bradykinin and nerve growth factor play pivotal roles in muscular mechanical hyperalgesia after exercise (delayed-onset muscle soreness). J Neurosci 2010; 30: 3752-3761.
23. Randall LO, Selitto JJ,. A method for measurement of analgesic activity on inflamed tissue. Arch Int Pharmacodyn Ther 1957; 111: 409-419.
24. Parada CA, Yeh JJ, Joseph EK, Levine JD,. Tumor necrosis factor receptor type-1 in sensory neurons contributes to induction of chronic enhancement of inflammatory hyperalgesia in rat. Eur J Neurosci 2003; 17: 1847-1852. (Pubitemid 36645334)
25. Papir-Kricheli D, Frey J, Laufer R, et al. Behavioural effects of receptor-specific substance P agonists. Pain 1987; 31: 263-276.
26. Mestre C, Pelissier T, Fialip J, et al. A method to perform direct transcutaneous intrathecal injection in rats. J Pharmacol Toxicol Methods 1994; 32: 197-200.
27. Hylden JL, Wilcox GL,. Intrathecal morphine in mice: a new technique. Eur J Pharmacol 1980; 67: 313-316. (Pubitemid 10007057)
28. Khasar SG, Gold MS, Levine JD,. A tetrodotoxin-resistant sodium current mediates inflammatory pain in the rat. Neurosci Lett 1998; 256: 17-20. (Pubitemid 28535393)
29. Malik-Hall M, Dina OA, Levine JD,. Primary afferent nociceptor mechanisms mediating NGF-induced mechanical hyperalgesia. Eur J Neurosci 2005; 21: 3387-3394. (Pubitemid 40961433)
30. Cata JP, Weng HR, Lee BN, et al. Clinical and experimental findings in humans and animals with chemotherapy-induced peripheral neuropathy. Minerva Anestesiol 2006; 72: 151-169.
31. Loprinzi CL, Maddocks-Christianson K, Wolf SL, et al. The Paclitaxel acute pain syndrome: sensitization of nociceptors as the putative mechanism. Cancer J 2007; 13: 399-403.
32. Leonard GD, Wright MA, Quinn MG, et al. Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer. BMC Cancer 2005; 5: 116.
33. Oki Y, McLaughlin P, Pro B, et al. Phase II study of oxaliplatin in patients with recurrent or refractory non-Hodgkin lymphoma. Cancer 2005; 104: 781-787. (Pubitemid 41113678)
34. Lehky TJ, Leonard GD, Wilson RH, et al. Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve 2004; 29: 387-392. (Pubitemid 38269758)
35. Park SB, Lin CS, Krishnan AV, et al. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain 2009; 132: 2712-2723.
36. Koike H, Mori K, Misu K, et al. Painful alcoholic polyneuropathy with predominant small-fiber loss and normal thiamine status. Neurology 2001; 56: 1727-1732. (Pubitemid 32574574)
37. Koike H, Iijima M, Sugiura M, et al. Alcoholic neuropathy is clinicopathologically distinct from thiamine-deficiency neuropathy. Ann Neurol 2003; 54: 19-29. (Pubitemid 36764978)
38. Ortiz-Plata A, Palencia G, Garcia E, et al. Ultrastructural changes in limb distal nerves of rats with alcoholism and/or malnutrition before and after dietary correction. J Appl Toxicol 1998; 18: 89-92. (Pubitemid 28168267)
39. Berger AR, Arezzo JC, Schaumburg HH, et al. 2â,3â- dideoxycytidine (ddC) toxic neuropathy: a study of 52 patients. Neurology 1993; 43: 358-362. (Pubitemid 23060270)
40. Windebank AJ, Grisold W,. Chemotherapy-induced neuropathy. J Peripher Nerv Syst 2008; 13: 27-46. (Pubitemid 351393018)
41. Shumilla JA, Liron T, Mochly-Rosen D, et al. Ethanol withdrawal- associated allodynia and hyperalgesia: age-dependent regulation by protein kinase C epsilon and gamma isoenzymes. J Pain 2005; 6: 535-549. (Pubitemid 41111728)
42. Urtado MB, Gameiro GH, Tambeli CH, et al. Involvement of peripheral TRPV1 in TMJ hyperalgesia induced by ethanol withdrawal. Life sciences 2007; 81: 1622-1626. (Pubitemid 350116202)
43. Sieb JP, Gillessen T,. Iatrogenic and toxic myopathies. Muscle Nerve 2003; 27: 142-156. (Pubitemid 36169325)
44. Dina OA, Joseph EK, Levine JD, Green PG,. Mechanisms mediating vibration-induced chronic musculoskeletal pain analyzed in the rat. J Pain 2010; 11: 369-377.
45. Chen X, Green PG, Levine JD,. Neuropathic pain-like alterations in muscle nociceptor function associated with vibration-induced muscle pain. Pain 2010; 151: 460-466.
46. Penson RT, Kronish K, Duan Z, et al. Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. Int J Gynecol Cancer 2000; 10: 33-41. (Pubitemid 30219476)
47. Pusztai L, Mendoza TR, Reuben JM, et al. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine 2004; 25: 94-102. (Pubitemid 38096266)
48. Dina OA, Green PG, Levine JD,. Role of interleukin-6 in chronic muscle hyperalgesic priming. Neuroscience 2008; 152: 521-525.
49. Jun CD, Choi BM, Kim HM, Chung HT,. Involvement of protein kinase C during taxol-induced activation of murine peritoneal macrophages. J Immunol 1995; 154: 6541-6547.
50. Zong ZP, Fujikawa-Yamamoto K, Li AL, et al. Involvement of protein kinase C in taxol-induced polyploidization in a cultured sarcoma cell line. Eur J Pharmacol 2000; 394: 181-187. (Pubitemid 30195701)
51. Ali AS, Ali S, El-Rayes BF, et al. Exploitation of protein kinase C: a useful target for cancer therapy. Cancer Treat Rev 2009; 35: 1-8.
52. Bedikian AY, Plager C, Stewart JR, et al. Phase II evaluation of bryostatin-1 in metastatic melanoma. Melanoma Res 2001; 11: 183-188. (Pubitemid 32385823)
53. Lam AP, Sparano JA, Vinciguerra V, et al. Phase II study of paclitaxel plus the protein kinase C inhibitor bryostatin-1 in advanced pancreatic carcinoma. Am J Clin Oncol 2010; 33: 121-124.
54. Pavlick AC, Wu J, Roberts J, et al. Phase I study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory non-hematologic tumors. Cancer Chemother Pharmacol 2009; 64: 803-810.
55. Winegarden JD, Mauer AM, Gajewski TF, et al. A phase II study of bryostatin-1 and paclitaxel in patients with advanced non-small cell lung cancer. Lung Cancer 2003; 39: 191-196. (Pubitemid 36173620)
56. Ekinci FJ, Shea TB,. Selective activation by bryostatin-1 demonstrates unique roles for PKC epsilon in neurite extension and tau phosphorylation. Int J Dev Neurosci 1997; 15: 867-874. (Pubitemid 28116353)
57. Joseph EK, Reichling DB, Levine JD,. Shared mechanisms for opioid tolerance and a transition to chronic pain. J Neurosci 2010; 30: 4660-4666.